Guardant Health, Inc 8-K, filed Aug 5, 2021
Guardant Health, Inc. (GH)
About this 8-K
Guardant Health, Inc filed this 8-K on August 5, 2021, reporting on events of August 4, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 5, 2021
(
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, include area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Co-Chief Executive Officer
On August 5, 2021, Guardant Health, Inc. (the “Company”) announced that its Board of Directors (the “Board”) approved a Co-Chief Executive Officer (“Co-CEO”) leadership structure for the Company and that effective on August 5, 2021 (the “Effective Date”), the Company appointed AmirAli Talasaz as the Company’s Co-CEO and changed the title of Helmy Eltoukhy, the Company’s current Chief Executive Officer, to the Company’s Co-CEO. Dr. Talasaz has also announced his intent to resign from his position as Chief Operating Officer of the Company, effective as of the Effective Date, but he will continue to serve as President of the Company. Dr. Eltoukhy will lead the Company’s oncology division while Dr. Talasaz will oversee the Company’s screening division. As Co-CEOs, the compensation of Drs. Eltoukhy and Talasaz will remain unchanged. Information regarding the business experience and certain relationships and related transactions of Drs. Eltoukhy and Talasaz, as required under this section, is incorporated by reference to the definitive proxy statement for the Company’s 2021 Annual Meeting of Stockholders as filed with the Securities and Exchange Commission (the “SEC”) on April 29, 2021.
Appointment of Meghan Joyce to the Board
Effective August 4, 2021, the Board increased the number of directors on the Board to eight and appointed Meghan Joyce as a Class II director of the Company. Ms. Joyce will serve on the Board for a term expiring at the 2023 Annual Meeting of Stockholders and until her successor is duly elected and qualified, or until her earlier death, resignation or removal. In connection with her appointment to the Board, Ms. Joyce was also appointed to the audit and compensation committees of the Board.
Ms. Joyce currently serves as the Chief Operating Officer and Executive Vice President of Platform at Oscar Health, a high-growth health tech and health insurance company, where she leads operations, technology, clinical, marketing, and new business lines. Prior to joining Oscar Health, Ms. Joyce held several leadership roles at Uber Technologies, most recently as Regional General Manager of the United States and Canada. Ms. Joyce has previously served as a Senior Policy Advisor at the United States Department of the Treasury, an investor at Bain Capital, and a consultant at Bain & Company. Ms. Joyce currently serves as a member of the Board of Directors of The Boston Beer Company, where she sits on the Audit Committee and chairs the Nominating and Governance Committee. She holds a master’s degree from Harvard Business School and a bachelor’s degree from Harvard College.
Ms. Joyce received the standard compensation paid by the Company to all of its non-employee directors under the Company’s Amended Non-Employee Director Compensation Program (the “Program”). Pursuant to the Program, Ms. Joyce received a stock option award and restricted stock unit award, each with a value of $362,500 (collectively, the “Initial Awards”). Each of the Initial Awards will vest with respect to one-fourth (1/4th) of the shares subject thereto on the first anniversary of Ms. Joyce’s appointment to the Board, and as to the remaining three-fourths (3/4ths) of the shares subject thereto on each monthly anniversary of Ms. Joyce’s appointment to the Board during the three-year period thereafter, subject to continued service through the applicable vesting date.
In accordance with the Company’s customary practice, the Company is entering into its standard form of indemnification agreement with Ms. Joyce, which will require the Company to indemnify her against certain liabilities that may arise as result of her status or service as a director. The description of Ms. Joyce’s indemnification agreement is qualified in its entirety by the full text of the form of indemnification agreement, which is attached to the Company’s Registration Statement on Form S-1/A filed with the SEC on September 18, 2018 as Exhibit 10.8.
There are no arrangements or understandings between Ms. Joyce and any other person pursuant to which she was selected as a director, nor are there any transactions in which Ms. Joyce has an interest that would be reportable under Item 404(a) of Regulation S-K.
Appointment of Chairperson of the Board
On August 5, 2021, Dr. Talasaz announced his intent to resign from his position as Chairperson of the Board, effective as of the Effective Date. Although Dr. Talasaz resigned from his position as Chairperson of the Board, he will retain his seat on the Board. Dr. Talasaz’s decision to resign from his position as Chairperson of the Board did not result from any disagreement with the Company, the Company’s management or the Board.
On August 5, 2021, the Board announced that it has appointed Dr. Eltoukhy to serve as Chairperson of the Board, effective as of the Effective Date. Dr. Eltoukhy currently serves as Chief Executive Officer and director of the Company.
On August 5, 2021, the Company issued a press release announcing these events, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
Description | |
| 99.1 | Press release of Guardant Health, Inc., dated August 5, 2021 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GUARDANT HEALTH, INC. | ||||||
| Date: August 5, 2021 | ||||||
| By: | /s/ John G. Saia | |||||
| John G. Saia | ||||||
| Senior Vice President, General Counsel and Corporate Secretary | ||||||
Exhibit 99.1
PRESS RELEASE
Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors
REDWOOD CITY, Calif.— August 5, 2021 (BUSINESS WIRE) — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced a new leadership structure to support the Company’s strategic objectives for future growth. Under this structure, Helmy Eltoukhy, CEO, and AmirAli Talasaz, President, will serve as co-CEOs of Guardant Health. Both Eltoukhy and Talasaz will continue to serve on the Board of Directors and Eltoukhy will assume the role of Chairman. In addition, Meghan Joyce, Chief Operating Officer and Executive Vice President of Platform at Oscar Health, will join the Company’s Board as an Independent Director.
Following the recent successful launch of new oncology products and the planned launch of a blood-based screening LDT in 2022, the Company has implemented a new leadership structure to support two focused areas within Guardant Health, Oncology and Screening, to be separately led by Eltoukhy and Talasaz, respectively. Furthermore, this structure will allow for scalability to address new areas across healthcare.
“Our mission at Guardant has always been to ensure patients have access to innovative oncology products. With the recent launches of Guardant Reveal, TissueNext and Response, that vision is clearer than ever, and we are still just scratching the surface of the need ahead,” said Eltoukhy. “We look forward to continuing to expand our product portfolio and improve patient outcomes as we conquer cancer with data across the continuum of care.”
“Early cancer screening has the potential to significantly transform patient outcomes. As we gain confidence in our screening platform and plan to launch an LDT in the near-term, it is clear that this opportunity requires a dedicated and focused effort,” said Talasaz. “We believe that Guardant will be a leader in blood-based screening, starting with CRC and expanding to other cancer types. This enhanced focus on execution will enable us to rapidly build the operational and commercial infrastructure required in this emerging business opportunity. I would also like to welcome Meghan to our Board of Directors. Her expertise in scaling high-growth organizations will be invaluable to our next phase of growth.”
“I am delighted to be joining Guardant’s Board of Directors at a momentous time as the company sets its sights on not only providing solutions for patients with advanced and early-stage cancer, but early cancer detection as well,” said Joyce. “Guardant is continuing to develop a portfolio of breakthrough products across all stages of the disease, and I look forward to applying my experience to help Guardant ensure these innovations are not only available but readily accessible for all patients.”
Meghan Joyce
Meghan Joyce is the Chief Operating Officer and Executive Vice President of Platform at Oscar Health, a high-growth health tech and health insurance company, where she leads operations, technology, clinical, marketing, and new business lines. Prior to joining Oscar Health, Joyce held several leadership roles at Uber Technologies, most recently as Regional General Manager of the United States and Canada. Meghan has previously served as a Senior Policy Advisor at the United States Department of the Treasury, an investor at Bain Capital, and a consultant at Bain & Company. Joyce currently serves as a member of the Board of Directors of The Boston Beer Company, where she sits on the Audit Committee and chairs the Nominating and Governance Committee. She holds a master’s degree from Harvard Business School and a bachelor’s degree from Harvard College.
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements relating to Guardant Health’s future results, or regarding the potential benefits and advantages of Guardant Health’s platforms, assays and tests, which involve risks and uncertainties that could cause Guardant Health’s actual results to differ materially from the expectations expressed in these forward-looking statements. These statements are based on current expectations and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to the Company as of the date hereof, and the Company disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Investor Contact:
Carrie Mendivil
investors@guardanthealth.com
Media Contact:
Anna Czene
press@guardanthealth.com